UroGen Pharma (URGN) Asset Writedowns and Impairment (2022)
UroGen Pharma (URGN) posted quarterly Asset Writedowns and Impairment of $255000.0 for Q4 2022, down 27.14% on a QoQ basis from $350000.0 in Q3 2022.
UroGen Pharma (URGN) Asset Writedowns and Impairment (2022) Analysis & Trends
UroGen Pharma (URGN) has reported Asset Writedowns and Impairment for 1 consecutive years, with $255000.0 the latest figure, recorded in Q4 2022.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $255000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2023 was $605000.0 (changed 0.0% YoY) and the FY2022 annual result came in at $870000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment retreated to $255000.0 in Q4 2022 per URGN's latest filing, from $350000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for URGN reached as high as $350000.0 in Q3 2022 and fell as low as $255000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | UroGen Pharma | 2.08 Bn | 1.94 Bn | 46.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 255,000.00 |
| Dec 31, 2022 | 255,000.00 |
| Sep 30, 2022 | 350,000.00 |
| Sep 30, 2022 | 350,000.00 |